Current Understanding of Resistance to Abiraterone and Enzalutamide in Advanced Prostate Cancer

被引：0
|
作者：
Antonarakis, Emmanuel S. [1 ]
机构：
[1] Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Oncol & Urol, Baltimore, MD 21287 USA
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2016年 / 14卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：316 / 319
页数：4
相关论文
共 50 条
  • [31] Hospitalizations Among Veterans Treated for Metastatic Prostate Cancer With Abiraterone or Enzalutamide
    Riekhof, Forest
    Yan, Yan
    Bennett, Charles L.
    Sanfilippo, Kristen M.
    Carson, Kenneth R.
    Chang, Su-Hsin
    Georgantopoulos, Peter
    Luo, Suhong
    Govindan, Srinivas
    Cheranda, Nina
    Afzal, Amber
    Schoen, Martin W.
    CLINICAL GENITOURINARY CANCER, 2024, 22 (02) : 18 - 26.e3
  • [32] Mefformin enhances the anti-prostate cancer activity of abiraterone and enzalutamide
    Xie, Yi
    Wang, Linbo
    Hussain, Arif
    CANCER RESEARCH, 2016, 76
  • [33] AR aberrations and resistance to abiraterone or enzalutamide
    Gerhardt Attard
    Emmanuel S. Antonarakis
    Nature Reviews Urology, 2016, 13 : 697 - 698
  • [34] Duration of Treatment in Prostate Cancer Patients Treated with Abiraterone Acetate or Enzalutamide
    Pilon, Dominic
    Behl, Ajay S.
    Ellis, Lorie A.
    Emond, Bruno
    Lefebvre, Patrick
    Dawson, Nancy A.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2017, 23 (02): : 225 - 225
  • [35] AR aberrations and resistance to abiraterone or enzalutamide
    Attard, Gerhardt
    Antonarakis, Emmanuel S.
    NATURE REVIEWS UROLOGY, 2016, 13 (12) : 697 - +
  • [36] Abiraterone or Enzalutamide for Patients With Metastatic Castration-Resistant Prostate Cancer
    La, Jennifer
    Wang, Lin
    Corrigan, June K.
    Lang, Deborah
    Lee, Michelle H.
    Do, Nhan V.
    Brophy, Mary T.
    Paller, Channing J.
    Fillmore, Nathanael R.
    JAMA NETWORK OPEN, 2024, 7 (08)
  • [37] Severe neutropenia probably caused by enzalutamide and abiraterone in a prostate cancer patient
    Somoza-Fernandez, Beatriz
    Escudero-Vilaplana, Vicente
    Collado-Borrell, Roberto
    Perez-Ramirez, Sara
    Villanueva-Bueno, Cristina
    Montero-Anton, Maria del Pilar
    Herranz-Alonso, Ana
    Sanjurjo-Saez, Maria
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2024, 30 (07) : 1268 - 1273
  • [38] Cardiovascular events among patients with prostate cancer treated with abiraterone and enzalutamide
    Baser, Onur
    Samayoa, Gabriela
    Dwivedi, Archana
    AlSaleh, Sara
    Cigdem, Burhan
    Kizilkaya, Erdi
    ACTA ONCOLOGICA, 2024, 63 : 137 - 146
  • [39] Genetic alternations correlated with resistant to abiraterone and enzalutamide in metastatic prostate cancer
    Shao, Yu-Hsuan Joni
    Hsiao, Tzu-Hung
    Ou, Yen-Chuan
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 133 - 133
  • [40] Use of abiraterone and enzalutamide beyond PSA progression in metastatic prostate cancer
    Becker, Daniel Jacob
    Iyengar, Arjun
    Zaman, Anika
    Ng, Jason
    Becker, Kevin Douglas
    Makarov, Danil V.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345